Effect of Dotinurad in Hyperuricemia With Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

Also called NCT06834230

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 360 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06834230
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06834230. Randomized; no masking; primary purpose treatment. Start 2025-03-28 (actual); primary completion 2027-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dotinurad in Hyperuricemia With Hypertension
Acronym
DIANA-NEXT
Condition
Hyperuricemia or Gout
Condition
Hypertension
Intervention (Drug)
Dotinurad
Intervention (Drug)
Febuxostat
Lead sponsor
Saga University (class: other)

Record details

Record id
cardio:ct-nct06834230
Content hash
f17e78cbcd9815a5ddbf643815b57b697f2af2f510d93f2154323397e234a507